Alemtuzumab News and Research

RSS
FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA accepts Genzyme’s LEMTRADA sBLA for review

Lymphocyte clue to multiple sclerosis drug response

Lymphocyte clue to multiple sclerosis drug response

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with CLL

Caution over monoclonal antibody treatment for MS

Caution over monoclonal antibody treatment for MS

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Genzyme receives Refuse to File letter from FDA for LEMTRADA

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Alemtuzumab as effective as other more expensive immune suppressants for kidney transplants

Alemtuzumab as effective as other more expensive immune suppressants for kidney transplants

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Sanofi-aventis acquires Genzyme

Sanofi-aventis acquires Genzyme

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Sanofi-aventis enters definitive agreement to acquire Genzyme

Sanofi-aventis enters definitive agreement to acquire Genzyme